Outsourcing Pharma
DECEMBER 23, 2020
The analytical tool, developed via Bionano Genomics, maps structural variations in DNA that are known to cause disease and are tied to symptom severity.
pharmaphorum
DECEMBER 23, 2020
NHS leaders have written to the UK prime minister urging him to extend the Brexit transition period by a month to avoid plunging the healthcare service into chaos on 1 January. The letter, published today by the NHS Confederation – a membership organisation representing NHS leaders from all parts of the health service, outlines concerns about the impact a no-deal outcome will have on delivering care to patients amid winter pressures and a rapid rise in COVID-19 infections. “The failu
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Mirror
DECEMBER 23, 2020
Davis, CA: Botanical Solution Inc. (BSI), innovator of sustainable, highly consistent and cost effective Advanced Botanical Materials, has successfully secured $3.3 million in a seed round of funding, and is planning another round of funding for Spring 2021. The Spring 2021 Round of funding will boost BSI’s proven ability to discover and develop novel botanical products that are sustainable, highly consistent and cost effective.
Pharma Marketing Network
DECEMBER 21, 2020
Stephen Towers, PhD is a leader in medical communications and healthcare marketing, with extensive experience in developing promotional medical education programs and medical affairs initiatives across numerous therapeutic areas and on behalf of diverse US healthcare organizations, from large pharmaceutical companies to smaller biotechs. As VP at Chameleon Communications (part of Omnicom Health Group), he leverages his scientific acumen and pharmaceutical expertise to create impactful scientific
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Outsourcing Pharma
DECEMBER 22, 2020
A leader from the IQVIA company explains how the boom in the volume and quality of data, and advanced analysis, can speed and streamline drug development.
pharmaphorum
DECEMBER 24, 2020
The UK’s COVID-19 vaccination programme could get a speed boost, with the country’s drugs regulator expected to make a decision on a shot from Oxford University/AstraZeneca in the next few days. If the vaccine becomes available the UK will be able to step up its vaccination programme as large swathes of the country face draconian “Tier 4” restrictions due to the emergence of as more infectious variant.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharma Marketing Network
DECEMBER 21, 2020
Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e., those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies. With over 100 late-stage gene therapy trials underway and an increasing number of gene-editing technologies entering trials, it’s clear that this trickle will soon become a torrent.
Outsourcing Pharma
DECEMBER 23, 2020
Three leaders from pharma ingredients and innovation firm Lonza share views on challenges and opportunities likely to face the industry in coming months.
pharmaphorum
DECEMBER 21, 2020
2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout of Celegne and AbbVie’s acquisition of Allergan – accounted for almost 40% of total M&A deal values. That said, there were still some interesting moves indicating new directions of travel for big pharma players – with most deals focused on specific drugs from biotechs, particularly in cancer (though we did get rumours of an AstraZeneca-Gilead merger , which would have been the
Med Ed 101
DECEMBER 23, 2020
I had this question the other day about the extent of tiotropium systemic absorption and I had to double-check. I knew that there was some, but wasn’t sure how prevalent it was. According to an older article, the tiotropium systemic absorption is approximately 20% (19.5% to be exact). The more important question is what does […]. The post Tiotropium Systemic Absorption – How Much?
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
DECEMBER 22, 2020
Rekambys plus Vocabria authorised to treat HIV-1 infections in adults who are virologically suppressed
Outsourcing Pharma
DECEMBER 22, 2020
A new survey from the supply-chain analysis company revals inefficiencies, inaccurate data and other flaws can be costly in terms of revenue, reputation and patient lives.
pharmaphorum
DECEMBER 24, 2020
Reviewing 2019’s key digital health stories last year I suggested that, while big strides continued to be made, any definitive ‘coming of age’ moment for the sector was unlikely. But that was before the first reports emerged of a highly contagious coronavirus and 2020 will be forever associated with COVID-19 and the global devastation and disruption it has wrought.
Med Ed 101
DECEMBER 20, 2020
Diarrhea is a nuisance that can lead to non-adherence to drug therapy. In some cases, diarrhea can be even more than a nuisance and may risk the lives of our patients. Below, I outline my top 5 drugs that cause diarrhea. Metformin When considering drugs that cause diarrhea, I want to give you the most […]. The post My Top 5 Drugs That Cause Diarrhea appeared first on Med Ed 101.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharma Times
DECEMBER 22, 2020
Murepavadin is being developed to treat Pseudomonas aeruginosa infections in people with cystic fibrosis
Outsourcing Pharma
DECEMBER 21, 2020
A partnership between Immunai and 10x Genomics will use artificial intelligence to create a map of the immune system to help accelerate drug development.
pharmaphorum
DECEMBER 21, 2020
Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. Just who are these companies and who is behind them, asks Richard Staines. A year ago, the names Moderna and BioNTech were known mainly to those who followed biotech and pharma dealings. But the tragic events of 2020 have meant these companies have become household names as their trailblazing mRNA vaccines became the first to be approved by regulators against t
Pharma Marketing Network
DECEMBER 22, 2020
What will stay the same in 2021? “COVID accelerated our 5-year digital transformation plan into a 5-month plan”. That client comment was amazingly accurate. While initially we saw a great deal of uncertainty with clients all responding differently, by April clients were forming strategic plans to adapt. By July, an intense focus on digital emerged and the rest of 2020 has been a whirlwind of activity as budgets shifted toward digital.
Pharma Times
DECEMBER 21, 2020
EGFR-TKI approved in the US for early non-small cell lung cancer
Outsourcing Pharma
DECEMBER 21, 2020
The pharma firm will lend support to Aqemiaâs high-tech drug discovery tools in order to work on discovery and development of therapies for the virus.
pharmaphorum
DECEMBER 24, 2020
Just a few weeks after its EU approval for heart failure, AstraZeneca’s Forxiga has been backed by NICE for this use by the NHS in England and Wales. Forxiga (dapagliflozin) – originally developed as a type 2 diabetes drug – is the first SGLT2 inhibitor to be approved for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without diabetes.
pharmaphorum
DECEMBER 23, 2020
French pharmaceutical company Servier has swooped on Agios Pharma’s marketed and experimental cancer drugs, buying the entire franchise in a deal that leaves the US biopharma focused on genetic disorders. It’s a major change of direction for Boston-based Agios, which has been concentrating on the oncology market since its inception in 2008, bringing the Bristol Myers Squibb-partnered Tibsovo (ivosidenib) for IDH1-mutant acute myeloid leukaemia to the US market.
pharmaphorum
DECEMBER 23, 2020
It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. But there was some considerable progress in other fields of medicine even though research efforts were diverted away, reports Richard Staines. The American Society of Clinical Oncology (ASCO) annual conference was one of the highlights of the year in cancer research and the fact it was held virtually did not distract from some stunni
pharmaphorum
DECEMBER 21, 2020
As expected, the FDA has moved swiftly ahead with emergency approval of Moderna’s COVID-19 vaccine after a positive assessment at its vaccines advisory committee. The authorisation means that around six million more vaccine doses can now be rolled out in the US coronavirus immunisation programme, adding to the almost three million doses of Pfizer/BioNTech’s already-approved shot which started to be administered a few days ago.
pharmaphorum
DECEMBER 22, 2020
The UK government is funding a network of three centres that will use digital technology to train the next generation of scientists specialising in advanced therapies. The National Horizons Centre, RoslinCT and the University of Birmingham have been selected as preferred bidders to deliver high impact physical and digitally-delivered training courses as part of the growing Advanced Therapies Skills Training Network (ATSTN) programme.
pharmaphorum
DECEMBER 22, 2020
The trials and tribulations of 2020 have brought the vital role of research, pharma, and biotech into sharp focus. But how has the push to develop treatments and vaccines for SARS-CoV-2 affected the industry’s commitment to patient centricity? This time last year, researchers and industry players were working hard to embed patient centricity and engagement into their everyday work.
pharmaphorum
DECEMBER 24, 2020
A serotonin sensor designed using Artificial Intelligence (AI) could help scientists study sleep and mental health and potentially find new neurology drugs. The US National Institutes of Health said that the research it had co-funded used AI to transform a bacterial protein into a new research tool. It is hoped that the protein, which “catches” serotonin molecules and allows them to be tracked, could detect subtle, real-time changes in serotonin levels during sleep, fear and social interactions.
pharmaphorum
DECEMBER 21, 2020
More than 1,000 NHS patients have booked flu vaccinations using a virtual assistant as part of a pilot project in the south east of England. The pilot project, run in collaboration with GP practices in Buckinghamshire, Brent, and Greenwich, involved patients using the Ask NHS app, which is already used by more than 375,000 patients. Patients in the pilot used the app developed by Sensely to self-check eligibility and quickly make appointments for flu jabs.
pharmaphorum
DECEMBER 22, 2020
BioNTech CEO Ugur Sahin has said that it is “highly likely” the company’s COVID-19 vaccine will work against the more infectious strain circulating in the south east of England, although further studies will be needed. Sahin was addressing a news conference after the vaccine was approved by the European Union, three weeks after the shot was independently backed by the UK’s regulator.
pharmaphorum
DECEMBER 23, 2020
Verily is planning “significant and focused growth” in 2021 after closing a $700 million funding round from investors including its parent company, and Google holding firm, Alphabet. The capital injection will support wide-ranging plans for the new year that include several life sciences programmes in surgery, pathology and immunology, which would add to the digital ophthalmology joint venture it signed with Japan’s Santen in February.
pharmaphorum
DECEMBER 21, 2020
Two weeks ago, Vicore reported mid-stage data showing that its lead drug C21 could boost the benefit of steroid therapy in treating COVID-19. Now, it has new data from the trial to back up that promise, and says the drug could act as a “complement” to coronavirus vaccines. Carl-Johan Dalsgaarl. The Swedish biotech’s chief executive Carl-Johan Dalsgaarl said on a conference call that the extended analysis from the ATTRACT trial reinforced earlier data showing that C21 reduced the need for supplem
pharmaphorum
DECEMBER 21, 2020
In a deal that could top $1 billion, Merck & Co has teamed up with US biotech Janux Therapeutics to bring T-cell immunotherapies to cancer patients. The agreement sees San Diego-based Janux in line for around $500 million in milestones apiece for two T-cell engager therapies – which bind to a tumour cell and recruit a patient’s T cells to eradicate tumour cells – that will be developed using Janux’ TRACTr platform.
pharmaphorum
DECEMBER 24, 2020
Amgen has decided that a drug for leprosy and tuberculosis it inherited as part of its acquisition of Celgene’s psoriasis blockbuster Otezla last year would fare better in the hands of a non-profit company, dedicated to bringing affordable medicines to poorer countries. AMG 634 – a PDE4 inhibitor being investigated for TB and leprosy complication erythema nodosum leprosum (ENL) – is being licensed to Australia’s Medicines Development for Global Health (MDGH), with Amgen surrendering all rights t
pharmaphorum
DECEMBER 24, 2020
Bristol Myers-Squibb has put out another downbeat “update” announcement about its immunotherapy Opdivo in an aggressive form of brain cancer, saying that it looks unlikely to produce a survival benefit in the disease. BMS said an independent committee had reviewed data from the phase 3 CheckMate-548 trial in newly diagnosed MGMT-methylated glioblastoma multiforme and concluded that it would be unlikely to meet its primary overall survival (OS) goal.
Expert insights. Personalized for you.
142 
Let's personalize your content